Hoth Therapeutics (HOTH)
Develops early-stage therapies for oncology, inflammatory, neurologic, dermatologic, and metabolic needs.
Something off on this page? Send us feedback.
Hoth Therapeutics is a clinical-stage biopharmaceutical company developing licensed and internally advanced drug candidates for oncology supportive care, mast-cell diseases, neuroinflammation, eczema, allergies, and metabolic disorders. Its lead HT-001 program is in a phase 2a trial, while commercialization remains dependent on clinical, regulatory, manufacturing, and financing execution.
Hoth Therapeutics is a Hoboken, New Jersey-based clinical-stage biopharmaceutical company developing therapies for unmet medical needs. Its lead work centers on HT-001, a topical formulation in a phase 2a trial for rash and other skin disorders associated with EGFR inhibitor cancer therapy, with European trial expansion approved in early 2026. Hoth is also preparing HT-KIT, a KIT-targeting program for mast-cell neoplasms and anaphylaxis, through IND-enabling toxicology and manufacturing work; it holds FDA orphan drug designation for mastocytosis.
Additional assets address Alzheimer’s and neuroinflammatory disease, eczema, asthma and allergies, and obesity or related metabolic conditions. The company has not commercialized products or generated product-sales revenue, so progress depends on trial execution, regulatory acceptance, licensed intellectual property, third-party manufacturing, and continued financing.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $7.9M · Total debt $0 · Total assets $9.6M · Shareholders' equity $8.2M
- Revenue
- $0
- Operating income
- −$3.8M
- Net income
- −$3.8M
No dividends on record.
| Institutions19 holders · as of Mar 31, 2026 | ≥ 3.16% | 786.8K shares | |
| Insiders1 holder · as of Feb 23, 2022 | 0.15% | 36.5K shares | |
| Otherremainder | ≤ 96.69% | 24.07M shares |
24.90M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (24.90M in the company's Sep 3, 2026 report, 13.26M elsewhere); stakes use the report.
Institutional filings for RKTO (100% of the company) are not on file here, so the institutional figure is a floor.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Geode Capital Management, LLCInstitution | 0.86% | 214,244 | 13Fas of Mar 31, 2026 |
UBS Group AGInstitution | 0.63% | 157,977 | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 0.52% | 129,691 | 13Fas of Mar 31, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.34% | 84,318 | 13Fas of Mar 31, 2026 |
State Street CorpInstitution | 0.26% | 63,939 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
Not reported.